Menu Back toHow Has FDARA Section 504 (RACE Act) Changed the Pediatric Oncology Landscape?

DIA 2021 Global Annual Meeting

How Has FDARA Section 504 (RACE Act) Changed the Pediatric Oncology Landscape?

Session Chair(s)

Scott  Greenfeder, PhD

Scott Greenfeder, PhD

  • Vice President, Oncology Regulatory Affairs
  • Bayer US LLC, United States
The implementation of FDARA Section 504 (RACE Act) requires a paradigm shift in pediatric oncology. Sharing experience and exploring potential room for improvement is essential to allow timely access to cancer treatments for children.
Learning Objective : Discuss how the RACT Act has affected pediatric oncology programs since implementation; Explore where further guidance might be helpful in pediatric oncology drug development; Discuss what else might be needed for timelier access to pediatric cancer treatments.


Pamela  Balcazar, MS

FDA Update

Pamela Balcazar, MS

  • Health Scientist, Oncology Center of Excellence, OC
  • FDA, United States
David  Nguyen, PharmD, MBA

Industry Update

David Nguyen, PharmD, MBA

  • Associate Director, Global Regulatory Lead - Oncology
  • Bristol-Myers Squibb Company, United States
Melodi J McNeil, MS, RPh

Measuring, Managing, and Moving Forward

Melodi J McNeil, MS, RPh

  • Director, Regulatory Policy and Intelligence
  • AbbVie, Inc., United States
Gregory  Reaman, DrMed, MD

FDA Update

Gregory Reaman, DrMed, MD

  • Associate Director for Pediatric Oncology , OCE, OC
  • FDA, United States